Invitae Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Invitae stock.
View analyst ratings for Invitae or view top-rated stocks.

Wall Street analysts have given Invitae a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Invitae wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Invitae saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 26,850,000 shares, a decrease of 15.3% from the June 30th total of 31,700,000 shares. Based on an average trading volume of 3,500,000 shares, the days-to-cover ratio is presently 7.7 days. Currently, 13.6% of the shares of the stock are sold short.
View Invitae's Short Interest.

Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Invitae.

Invitae will be holding an earnings conference call on Tuesday, August 3rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Invitae Co. (NYSE:NVTA) posted its earnings results on Tuesday, May, 4th. The medical research company reported ($0.63) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.03. The medical research company earned $103.60 million during the quarter, compared to analyst estimates of $101.46 million. Invitae had a negative net margin of 194.99% and a negative trailing twelve-month return on equity of 31.82%. Invitae's revenue for the quarter was up 61.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.03) EPS.
View Invitae's earnings history.

Invitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 71.0% and is now trading at $27.10.
View which stocks have been most impacted by COVID-19.

8 brokerages have issued twelve-month price objectives for Invitae's shares. Their forecasts range from $33.00 to $58.00. On average, they expect Invitae's stock price to reach $43.38 in the next year. This suggests a possible upside of 60.1% from the stock's current price.
View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts.

59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees.

Some companies that are related to Invitae include Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Fulgent Genetics (FLGT), Veracyte (VCYT), Burning Rock Biotech (BNR), RadNet (RDNT), Castle Biosciences (CSTL), Renalytix AI (RNLX), Genetron (GTH), DermTech (DMTK), Personalis (PSNL) and Celcuity (CELC).
View all of NVTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), The Trade Desk (TTD), Shopify (SHOP), salesforce.com (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include Harel Insurance Investments & Financial Services Ltd. (0.01%), Boyd Watterson Asset Management LLC OH (0.00%) and Compagnie Lombard Odier SCmA (0.00%). Company insiders that own Invitae stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for Invitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Harel Insurance Investments & Financial Services Ltd., and Boyd Watterson Asset Management LLC OH. Company insiders that have sold Invitae company stock in the last year include Artur Bergman, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for Invitae or view top insider-selling stocks.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $27.10.

Invitae has a market capitalization of $5.42 billion and generates $279.60 million in revenue each year. The medical research company earns $-602,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

Invitae employs 2,100 workers across the globe.

The official website for Invitae is www.invitae.com.

Invitae is headquartered at 1400 16th Street, SAN FRANCISCO CA, 94103.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]